These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1709685)

  • 41. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study.
    Weick JK; Dahlberg S; Fisher RI; Dana B; Miller TP; Balcerzak SP; Pierce HI
    J Clin Oncol; 1991 May; 9(5):748-53. PubMed ID: 1707955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
    Gutiérrez J; Osorio G; García H; Vacarezza R; Cao C
    Rev Med Chil; 1991 Sep; 119(9):990-1000. PubMed ID: 1726958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma.
    O'Reilly SE; Klimo P; Connors JM
    J Clin Oncol; 1991 May; 9(5):741-7. PubMed ID: 1707954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations.
    Connors JM; Klimo P
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):41-6. PubMed ID: 2456622
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
    Gordon LI; Anderson J; Habermann TM; Winter JN; Glick J; Schilder RJ; Cassileth P
    J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
    Hagemeister FB
    Leuk Lymphoma; 1993; 10 Suppl():21-7. PubMed ID: 7683228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
    De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
    J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
    [TBL] [Abstract][Full Text] [Related]  

  • 50. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma.
    Martelli M; Guglielmi C; Coluzzi S; Avvisati G; Amadori S; Giovannini M; Torromeo C; Mandelli F
    J Clin Oncol; 1993 Dec; 11(12):2362-9. PubMed ID: 7504091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.
    Hirano M; Okamoto M; Maruyama F; Ezaki K; Shimizu K; Ino T; Matsui T; Sobue R; Shinkai K; Miyazaki H
    Cancer; 1992 Feb; 69(3):772-7. PubMed ID: 1370393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CAVBP/DEP alternating chemotherapy for the treatment of intermediate and high grade non Hodgkin's lymphoma: final results of a pilot study.
    Palmieri G; Caponigro F; Iaffaioli RV; Contegiacomo A; Montesarchio V; Lauria R; Calderopoli R; Pagliarulo C; Gridelli C; Bianco AR
    Hematol Oncol; 1990; 8(6):313-22. PubMed ID: 1704869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation.
    Macpherson N; Lesack D; Klasa R; Horsman D; Connors JM; Barnett M; Gascoyne RD
    J Clin Oncol; 1999 May; 17(5):1558-67. PubMed ID: 10334544
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy.
    Shipp MA; Klatt MM; Yeap B; Jochelson MS; Mauch PM; Rosenthal DS; Skarin AT; Canellos GP
    J Clin Oncol; 1989 May; 7(5):613-8. PubMed ID: 2468746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ProMACE-C-MOPP in aggressive non-Hodgkin's lymphoma. Long-term results in 45 patients treated in a single institution.
    Carrión JR; Delgado JR; Dominguez S; Flores E; Garcia P; Jaen J; Santos JA
    Acta Oncol; 1991; 30(7):823-9. PubMed ID: 1764274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).
    Bernstein JI; Coleman CN; Strickler JG; Dorfman RF; Rosenberg SA
    J Clin Oncol; 1986 Jun; 4(6):847-58. PubMed ID: 3711961
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results.
    Guglielmi C; Amadori S; Martelli M; Dragoni F; Mandelli F
    Ann Oncol; 1991 May; 2(5):365-71. PubMed ID: 1954181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen.
    Sparano JA; Wiernik PH; Strack M; Leaf A; Becker N; Valentine ES
    Blood; 1993 May; 81(10):2810-5. PubMed ID: 8490187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up.
    Björkholm M; Hagberg H; Holte H; Kvaloy S; Teerenhovi L; Anderson H; Cavallin-Ståhl E; Myhre J; Pertovaara H; Ost A; Nilsson B; Osby E
    Ann Oncol; 2007 Jun; 18(6):1085-9. PubMed ID: 17363838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs.
    Salles G; Herbrecht R; Tilly H; Berger F; Brousse N; Gisselbrecht C; Coiffier B
    Am J Med; 1991 Jan; 90(1):77-84. PubMed ID: 1702581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.